Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Adult
Humans
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Docetaxel
Lung Neoplasms
/ drug therapy
Pemetrexed
/ therapeutic use
Cohort Studies
Quality of Life
Cost-Benefit Analysis
Technology Assessment, Biomedical
/ methods
Quality-Adjusted Life Years
Proto-Oncogene Proteins c-ret
/ genetics
Multicenter Studies as Topic
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
accepted:
24
01
2023
pubmed:
10
2
2023
medline:
22
3
2023
entrez:
9
2
2023
Statut:
ppublish
Résumé
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Roche) of pralsetinib (Gavreto
Identifiants
pubmed: 36757608
doi: 10.1007/s40273-023-01247-w
pii: 10.1007/s40273-023-01247-w
pmc: PMC10020319
doi:
Substances chimiques
Docetaxel
15H5577CQD
pralsetinib
0
Pemetrexed
04Q9AIZ7NO
RET protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-ret
EC 2.7.10.1
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
353-361Subventions
Organisme : Health Technology Assessment Programme
ID : NIHR135136
Informations de copyright
© 2023. The Author(s).
Références
Cancer. 2019 Nov 15;125(22):4019-4032
pubmed: 31381142
Lancet Oncol. 2021 Jul;22(7):959-969
pubmed: 34118197
Ann Oncol. 2022 Nov;33(11):1168-1178
pubmed: 35973665